L9 BioScience Inc.
Providing patients with safer and more effective medicines
What we do:
L9 BioScience is a technology that increases the bioavailability of Active Pharmaceutical Ingredients (API’s)
9-fold to 18-fold increase in API bioavailability
The L9 Process improves clinical outcomes, reduces toxicity and reduces cost
Up to 50% API retention without bioaccumulation
The L9 Process is patented, with 12 more discreet claims in the patent landscape
A product with a higher gastric absorption level allows you to take exponentially smaller dosages of a given vitamin, pharmaceutical or nutraceutical. Pharmaceuticals and Nutraceuticals often have deleterious side effects, so smaller doses equates to significantly less deleterious side effects.
The L9 Process allows one to re-patent originator drugs with new increased bioavailability.
The top 10 selling drugs whose patents have expired in 2020 total over $8 Billion. There are 56 drug patents expiring over the next 3 years.
This business model can be replicated over and over again with many other non-biological drugs, where drugs that have expired patents, may have the opportunity to be re-patented.